Compare MNPR & DCBO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MNPR | DCBO |
|---|---|---|
| Founded | 2014 | 2016 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 368.9M | 419.6M |
| IPO Year | 2019 | 2020 |
| Metric | MNPR | DCBO |
|---|---|---|
| Price | $53.06 | $17.99 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 9 |
| Target Price | ★ $107.00 | $32.00 |
| AVG Volume (30 Days) | ★ 168.5K | 113.1K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 54.99 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $12.89 |
| Revenue Next Year | N/A | $11.44 |
| P/E Ratio | ★ N/A | $22.04 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $28.40 | $14.39 |
| 52 Week High | $105.00 | $33.69 |
| Indicator | MNPR | DCBO |
|---|---|---|
| Relative Strength Index (RSI) | 39.70 | 53.52 |
| Support Level | $50.77 | $16.28 |
| Resistance Level | $60.67 | $20.15 |
| Average True Range (ATR) | 3.03 | 0.99 |
| MACD | -0.32 | 0.30 |
| Stochastic Oscillator | 25.60 | 70.96 |
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
Docebo Inc is a provider of cloud-based learning management systems. The solutions provided by the company allow learning administrators to deliver scalable and flexible personalized learning experiences, from formal training to social learning to multiple internal, external, and blended audiences. The group provides an easy-to-use, configurable, and affordable learning platform with the end-to-end capabilities and critical functionality needed to train both internal and external workforces, partners, and customers. The majority of the revenue is derived from customers based in North America.